COVID-19 VACCINE INFORMATION

Updated 1-28-2022

<u>All adult rheumatology patients</u> should receive COVID-19 vaccination unless there is a known contraindication (e.g. known allergies to vaccine components) per The American College of Rheumatology task force recommendation.

Additional vaccine dose recommendations for immune deficiency patients

- For moderate to severe immune deficiency patients
- This includes most rheumatology patients
- Avoid taking certain medications/treatments for 1-2 weeks after vaccine shot if possible (See below)
- A doctors note is <u>NOT</u> needed

If you received a Moderna or Pfizer (mRNA) 2 shot vaccine initially

- Get 3rd dose at least 28 days after second vaccine
- Get 4th dose (booster) at least 5 months after 3rd dose
- 3rd/4th doses may be either Moderna or Pfizer no matter which ones were given previously

If you received a J&J one shot vaccine initially

- Get 2nd vaccine (Moderna or Pfizer recommended) at least 2 months after 1st shot
- No additional doses recommended at this time

Avoid taking the following medications/treatments for 1-2 weeks after the booster (if you can)

- Methotrexate
- Cellcept (mycophenolate). cyclosporine, tacrolimus
- All biologics (eg. Remicade, Simponi, Orencia, Cimzia, Enbrel, Humira, Actemra, Cosentyx, Taltz, Stelara, Benlysta, Xeljanz, Rinvoq, Olumiant)
- Rituxan (talk to your provider about the timing of the booster)
- Plaquenil (hydroxychloroquine) does <u>NOT</u> need to be stopped
- Try to avoid Tylenol and NSAIDS 24 hours before booster

Additional treatment options for HIGH RISK patients with autoimmune inflammatory disease (discuss with your provider)

- Monoclonal antibody treatment <u>PRIOR</u> to getting Covid (with or without exposure)
- Monoclonal antibody (or other) treatment <u>WITH</u> Covid infection

Remember these are general guidelines/recommendations and may be individualized based on the needs of the patient, and are subject to change as new information becomes available

Please reach out to your provider for any questions regarding these recommendations.